分子诊断技术和靶向治疗在乳腺癌个体化治疗中的应用(4)
[13] Eniu A， Palmieri FM， Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer[J]. Oncoloqist， 2005， 10(9)： 665-685.
[14] Perez EA. Paclitaxel in breast cancer[J]. Oncoloqist， 1998， 3(6)： 373-389.
[15] Jones SE. Metastatic breast cancer： the treatment challenge[J]. Clin Breast Cancer， 2008， 8(3)： 224-233.
[16] Gralow J， Ruqo H， Gradishar W， et al. Novel taxane formulations in the treatment of breast cancer： a thought leader discussion and consensus round table[J]. Clin Breast Cancer， 2008， 8(1)： 33-37.
[17] Burgess DJ， Doles J， Zender L， et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo[J]. Proc Natl Acad Sci USA， 2008， 105(26)： 9053-9058.
[18] Sève P， Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents？[J]. Lancet Oncol， 2008， 9(2)： 168-175.
[19] Arai T， Miyoshi Y， Kim SJ， et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surq Oncol， 2008， 34(7)： 734-738.
[20] Hoffmann AC， Wild P， Leicht C， et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy[J]. Neoplasia， 2010， 12(8)： 628-636., 百拇医药(汪洁)
[14] Perez EA. Paclitaxel in breast cancer[J]. Oncoloqist， 1998， 3(6)： 373-389.
[15] Jones SE. Metastatic breast cancer： the treatment challenge[J]. Clin Breast Cancer， 2008， 8(3)： 224-233.
[16] Gralow J， Ruqo H， Gradishar W， et al. Novel taxane formulations in the treatment of breast cancer： a thought leader discussion and consensus round table[J]. Clin Breast Cancer， 2008， 8(1)： 33-37.
[17] Burgess DJ， Doles J， Zender L， et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo[J]. Proc Natl Acad Sci USA， 2008， 105(26)： 9053-9058.
[18] Sève P， Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents？[J]. Lancet Oncol， 2008， 9(2)： 168-175.
[19] Arai T， Miyoshi Y， Kim SJ， et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surq Oncol， 2008， 34(7)： 734-738.
[20] Hoffmann AC， Wild P， Leicht C， et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy[J]. Neoplasia， 2010， 12(8)： 628-636., 百拇医药(汪洁)